Abstract Number: 0080 • ACR Convergence 2021
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for…Abstract Number: 0081 • ACR Convergence 2021
Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies
Background/Purpose: Risk stratification in patients with antiphospholipid antibodies (aPL) remains a clinical challenge. We aim to evaluate the role of Thrombin Generation Assay (TGA) in…Abstract Number: 0082 • ACR Convergence 2021
Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)
Background/Purpose: Few studies have evaluated the role of environmental factors in APS. While antiphospholipid antibodies (aPL) may be induced by environmental stiumuli, e.g., viruses, cardiovascular…Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…Abstract Number: 0948 • ACR Convergence 2021
Immunometabolism of Neutrophils in Antiphospholipid Syndrome (APS)
Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) appear to play roles in APS pathophysiology. Until recently, it was thought that neutrophils relied…Abstract Number: 0069 • ACR Convergence 2021
First and Recurrent Thrombosis Risk After 3842 Patient-Years of Follow-Up: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (
Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…Abstract Number: 0949 • ACR Convergence 2021
Single-Cell RNA Sequencing of APS Skin Reveals Endothelial Pathology and Cellular Interactions
Background/Purpose: Although antiphospholipid syndrome (APS) regularly presents with discrete thrombotic events, many patients will also acquire organ damage over time secondary to occlusive neointimal formation…Abstract Number: 0070 • ACR Convergence 2021
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or…Abstract Number: 0950 • ACR Convergence 2021
Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/Racemosa
Background/Purpose: Endothelial proliferation is a key finding in antiphospholipid antibody (aPL)-positive patients with microvascular disease. The mTOR pathway plays a role in the endothelial proliferation…Abstract Number: 0071 • ACR Convergence 2021
Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: Damage Index in APS (DIAPS) is a scoring system developed to assess long-term damage in thrombotic primary antiphospholipid syndrome (PAPS), which also correlates with…Abstract Number: 0951 • ACR Convergence 2021
Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: Several antiphospholipid antibody (aPL) profiles are associated with a higher risk for the clinical manifestations of the antiphospholipid syndrome (APS). These include “triple positivity”…Abstract Number: 0072 • ACR Convergence 2021
Immunosuppression Use in Primary Antiphospholipid Antibody Positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: The APS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive…Abstract Number: 0962 • ACR Convergence 2021
Association of Antiphospholipid Antibodies with Thromboembolic Events and Severe Outcomes in COVID-19
Background/Purpose: Although several studies indicate that patients with COVID-19 produce antiphospholipid antibodies (aPL), it is unclear which aPL subtype predominates and whether aPL correlates with…Abstract Number: 0073 • ACR Convergence 2021
Anti-Domain 1 Antibody Fluctuation over Time in Patients with Persistently Positive Antiphospholipid Antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”)
Background/Purpose: Data on fluctuation of antibodies against domain 1 (anti-D1) of β2-glycoprotein I (β2GPI) are scarce. Patients with antiphospholipid syndrome (APS) and all three criteria…Abstract Number: 1285 • ACR Convergence 2021
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 19
- Next Page »